1. Medtech Insight
  2. >>Business
  3. >>Deals

Labcorp Buys Myriad Genetics’ Vectra Autoimmune Test Business

 
• By Reed Miller

Labcorp has agreed to pay $150m in cash for Myriad Genetics’ autoimmune business, one of three major units Myriad is unloading as it tries to narrow its focus to oncology, women's health and mental health diagnostics.

Rheumatoid arthritis , Gouty arthritis ( Film x-ray hand of child with arthritis at multiple joint ) - Image ID: F83CXB
• Source: Alamy

Labcorp is improving expanding its rheumatoid arthritis diagnostics lineup by acquiring the Vectra rheumatoid arthritis assay from Myriad Genetics, which is getting out of the autoimmune diagnostics business to devote more resources to its oncology, mental health and women’s health businesses.

Vectra is among the “select operating assets and intellectual property” from Myriad’s autoimmune business unit that Labcorp has agreed to buy for $150m in cash, the companies announced on 3...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Medtronic Eyes Up to $350M Tariff Hit in FY26, Leans On Cost Controls And Pricing Strategy

 
• By Shubham Singh

Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.

India-UK Free Trade Agreement Sets Stage For Medtech Growth, But Industry Demands Safeguards

 
• By Shubham Singh

Announced after three years of negotiation, the FTA eliminates tariffs on 99% of Indian product types, covering nearly all trade value, and reduces tariffs on 90% of UK products. Although not yet formally signed, the deal is being positioned by the Indian government as “transformative,” with an estimated economic impact of $6.4bn for the UK alone by 2040.

Medtronic To Spin Out Diabetes Unit As New Products Solidify Turn-Around Story

 
• By Shubham Singh

Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.